ResMed Inc. Q4 2026 Earnings Recap

Shares dropped 5.4% as investors reacted negatively to a cautious outlook and signs of deceleration in key metrics, despite management’s positive framing of revenue growth and margin expansion.

Key Takeaways

• Reported 9% headline revenue growth (8% constant currency) for Q4; fiscal 2026 saw 10% total revenue growth.
• Gross margins improved due to supply chain efficiencies, contributing to 180 basis points of operating margin expansion for the year.
• Non-GAAP EPS grew 16%, supported by operational execution.
• Guidance implied a more cautious outlook with emphasis on ongoing operational challenges and transformation work as core markets remain underpenetrated.
• Increasing patient demographic shifts and evolving market dynamics signal potential headwinds requiring investments in product and marketing adaptation.